154 related articles for article (PubMed ID: 21695640)
1. Small molecule allosteric modulators of phosphodiesterase 4.
Gurney ME; Burgin AB; Magnusson OT; Stewart LJ
Handb Exp Pharmacol; 2011; (204):167-92. PubMed ID: 21695640
[TBL] [Abstract][Full Text] [Related]
2. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
Burgin AB; Magnusson OT; Singh J; Witte P; Staker BL; Bjornsson JM; Thorsteinsdottir M; Hrafnsdottir S; Hagen T; Kiselyov AS; Stewart LJ; Gurney ME
Nat Biotechnol; 2010 Jan; 28(1):63-70. PubMed ID: 20037581
[TBL] [Abstract][Full Text] [Related]
3. Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.
Nankervis JL; Feil SC; Hancock NC; Zheng Z; Ng HL; Morton CJ; Holien JK; Ho PW; Frazzetto MM; Jennings IG; Manallack DT; Martin TJ; Thompson PE; Parker MW
Bioorg Med Chem Lett; 2011 Dec; 21(23):7089-93. PubMed ID: 22030030
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
5. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
6. Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains.
Bolger GB; Dunlop AJ; Meng D; Day JP; Klussmann E; Baillie GS; Adams DR; Houslay MD
Cell Signal; 2015 Apr; 27(4):756-69. PubMed ID: 25546709
[TBL] [Abstract][Full Text] [Related]
7. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.
Houslay MD; Adams DR
Biochem J; 2003 Feb; 370(Pt 1):1-18. PubMed ID: 12444918
[TBL] [Abstract][Full Text] [Related]
8. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK.
Li X; Vadrevu S; Dunlop A; Day J; Advant N; Troeger J; Klussmann E; Jaffrey E; Hay RT; Adams DR; Houslay MD; Baillie GS
Biochem J; 2010 Apr; 428(1):55-65. PubMed ID: 20196770
[TBL] [Abstract][Full Text] [Related]
9. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
11. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 4-alkynyl pyrazoles as inhibitors of PDE4: a practical access via Pd/C-Cu catalysis.
Gorja DR; Shiva Kumar K; Kandale A; Meda CL; Parsa KV; Mukkanti K; Pal M
Bioorg Med Chem Lett; 2012 Apr; 22(7):2480-7. PubMed ID: 22381049
[TBL] [Abstract][Full Text] [Related]
13. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
14. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA).
Collins DM; Murdoch H; Dunlop AJ; Charych E; Baillie GS; Wang Q; Herberg FW; Brandon N; Prinz A; Houslay MD
Cell Signal; 2008 Dec; 20(12):2356-69. PubMed ID: 18845247
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and molecular dynamics analyses of differences in inhibitor binding to human and nematode PDE4: Implications for management of parasitic nematodes.
Schuster KD; Mohammadi M; Cahill KB; Matte SL; Maillet AD; Vashisth H; Cote RH
PLoS One; 2019; 14(3):e0214554. PubMed ID: 30917179
[TBL] [Abstract][Full Text] [Related]
16. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.
Wang P; Myers JG; Wu P; Cheewatrakoolpong B; Egan RW; Billah MM
Biochem Biophys Res Commun; 1997 May; 234(2):320-4. PubMed ID: 9177268
[TBL] [Abstract][Full Text] [Related]
17. Novel 1-alkynyl substituted 1,2-dihydroquinoline derivatives from nimesulide (and their 2-oxo analogues): a new strategy to identify inhibitors of PDE4B.
Pal S; Durgadas S; Nallapati SB; Mukkanti K; Kapavarapu R; Meda CL; Parsa KV; Pal M
Bioorg Med Chem Lett; 2011 Nov; 21(21):6573-6. PubMed ID: 21920740
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
20. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
